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Abstract Reducing plasma levels of low-density
lipoprotein cholesterol (LDL-C) remains the cornerstone in
the primary and secondary prevention of cardiovascular
disease. However, lack of efficacy and adverse effects
mean that a substantial proportion of patients fail to
achieve acceptable LDL-C levels with currently available
lipid-lowering drugs. Over the last decade, inhibition of
proprotein convertase subtilisin/kexin type 9 (PCSK9) has
emerged as a promising therapeutic strategy to reduce
residual cardiovascular disease risk. Binding of PCSK9 to
the LDL receptor targets the receptor for lysosomal
degradation. The recognition that inhibition of PCSK9
increases LDL receptor activity has led to the development
of a number of approaches to directly target PCSK9.
Numerous monoclonal antibodies against PCSK9 are cur-
rently being evaluated in phase 3 trials, involving various
patient categories on different background lipid-lowering
therapies. Current evidence shows reductions in LDL-C
levels of up to 70 % may be achieved with PCSK9 inhi-
bition, independent of background statin therapy. This
review examines the most recent evidence and future
prospects for the use of PCSK9 inhibitors in the prevention
of cardiovascular disease.
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Introduction
Atherosclerotic cardiovascular disease (CVD) is the lead-
ing cause of mortality worldwide [1]. Atherosclerosis
occurs as a consequence of metabolic and inflammatory
changes to the arterial wall, which promote the macro-
phage-mediated intimal deposition of pro-atherogenic low-
density lipoprotein cholesterol (LDL-C), contributing to
plaque formation, limiting blood flow to vital organs and
increasing the risk of atherothrombotic and atheroembolic
sequelae. Dyslipidaemia has become an important risk
factor to target in both the primary and secondary pre-
vention of CVD. With the advent of statins, which inhibit
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase, sustained reductions in LDL-cholesterol have
become achievable. Large-scale clinical trials demonstrate
that a 40 mg dL-1 (1 mmol L-1) decrease in LDL-C
results in a 22 % reduction in adverse cardiovascular
events [2, 3]. The overwhelming evidence of the clinical
efficacy and cost-effectiveness of statins has led to their
establishment as the first-line treatment of dyslipidaemia
[4]. However, despite optimal statin therapy, less than half
of recurrent cardiovascular events can be prevented.
Indeed, satisfactory control of dyslipidaemia is not
achieved in certain patients, even with combination lipid-
lowering therapy.
Impelled by the need for additional lipid management
strategies, recent attention has focused on a new class of
agent, proprotein convertase subtilisin/kexin type 9
(PSCK9) inhibitors. These demonstrate much promise,
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particularly for those unable to take statins, e.g. due to
adverse effects or drug–drug interactions [5]. The discov-
ery of PCSK9-based therapies began in 2003, with an
astute clinical observation of a French family, which
demonstrated features of familial hypercholesterolemia
(FH), without mutations in the genes contemporaneously
recognised to cause FH; the LDL receptor gene (LDLR,
accounting for 95 % of FH defects), or apolipoprotein B
gene, encoding the protein that binds to the LDLR (ApoB,
accounting for 4 % of FH defects) [6, 7]. These findings
led to the identification of two novel missense mutations
that increased the activity of a serine protease enzyme,
originally called neural apoptosis-regulated convertase 1
(NARC-1) and subsequently renamed proprotein conver-
tase subtilisin/kexin type 9 [8]. This discovery has led to
novel therapeutic options in lipid management [9, 10]. The
goals of this review are to explore the mechanism of action
of PCSK9 inhibitors and their potential to improve car-
diovascular outcomes.
The structure and function of PCSK9
Synthesis and structure
PCSK9, found at chromosome 1p32, is 22 kb in length,
with 12 exons that encode a 692-amino acid protein [11]. It
is a proteinase K-like enzyme, belongs to the secretory
subtilase family and is primarily synthesised and secreted
by hepatocytes [12, 13]. The synthesis of PCSK9 is up-
regulated by sterol-regulatory-element-binding protein-2
(SREBP-2), a transcription factor that regulates PCSK9
expression by binding to the sterol-regulatory element in
the promoter region of the gene [14]. SREBP-2 also
increases LDL receptor and cholesterol synthesis, via the
activation of genes encoding key enzymes involved in
cholesterol homeostasis, including HMG-CoA reductase
[15]. It is activated by low intracellular cholesterol con-
centrations. SREBP-2 and PCSK9 expression is suppressed
in fasting mice fed a cholesterol-rich diet [16]. Prolonged
fasting in animals and humans, however, also causes a
decrease in PCSK9 and SREBP-2 activity [17]. In addition,
in vivo evidence suggests a possible role for insulin in
increasing the expression of PCSK9 [18].
The PCSK protein product is comprised of a N-terminal
signal peptide, prodomain, catalytic domain, hinge region,
and cysteine-rich C-terminal domain [13, 19]. Following
the removal of the signal peptide domain, PCSK9 is syn-
thesised as a *74 kDa zymogen, which undergoes auto-
catalytic cleavage in the endoplasmic reticulum and Golgi
body, to generate a pro-domain fragment and *62 kDa
mature protein, which remain strongly associated to one
another [20–22].
LDL receptor cycling
The first 8 members of the PCSK family, PCSK 1–8, are
serine proteases involved in the processing of inactive
precursor proteins to generate functional and bioactive
peptides, polypeptides and hormones, which play important
roles in regulating growth and metabolism [23–25]. In
contrast, PCSK9 plays a crucial role in the regulation of
LDL receptor recycling [26]. The PCSK9 complex binds to
the epidermal growth factor A (EGF-A) domain of the
LDL receptor, leading to the lysosomal degradation of the
latter and reduced clearance of circulating LDL-C. Extra-
hepatic actions of PCSK9 include enhancement of chy-
lomicron secretion and regulation of enterocyte cholesterol
balance [13]. Moreover, data from experimental models
suggest that the role of PCSK9 extends beyond lipid
homeostasis; it is implicated as a regulator of glucose
metabolism, liver regeneration and susceptibility to hep-
atitis C virus infection [27–30].
In mouse models, the accumulation of cholesteryl esters
in aortic atherosclerotic lesions was markedly reduced by
PCSK9 inactivation [31]. Conversely, overexpression of
PCSK9 induced an excess burden of atherosclerosis. In
LDLR-deficient mice, knockdown or overexpression of
PCSK9 had no significant effects on cholesteryl ester
accumulation or atheromatous plaque size. This study
strongly suggested that the process by which PCSK9
enhances atherosclerosis is primarily mediated by its action
on the LDLR [31]. Figure 1 displays normal, physiological
LDLR recycling.
In humans studies, PCSK9 loss-of-function mutations
have been associated with reductions in LDL-C and car-
diovascular events [32]. Conversely, those with high levels
of PCSK9 have higher level of plasma LDL-C and sig-
nificantly increased lifetime CVD risk [32]. Gain-of-func-
tion mutations on PCSK9 are associated with a severe form
of autosomal dominant hypercholesterolemia, phenotypi-
cally indistinguishable from FH due to LDL-receptor
mutations [32].
Regulation
PCSK9 concentrations demonstrate a diurnal rhythm syn-
chronous to cholesterol synthesis, with changes of ±15 %
from the mean value [33]. PCSK9 synthesis also induced
by insulin and repressed by glucagon in rodents [18]. In
healthy humans, PCSK9 levels are demonstrably reduced
with fasting (decreasing 60 % over 36 h), and increase in
the post-prandial period, suggesting a similar effect [33–
35]. In addition, PCSK9 is positively controlled by the
oxysterol-activated liver X receptor (LXR) [18, 36].
PCSK9 circulates in plasma in three main forms [37].
When secreted, PCSK9 exists as a monomer, but can self-
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associate into di- and trimeric complexes, facilitated by the
catalytic domain. It is present in free and protein-bound
forms in human plasma, with 40 % of circulating PCSK9
exclusively associated with LDL [16]. LDL-bound PCSK9
has diminished LDL receptor-binding activity. It has been
proposed that this is a regulatory mechanism, by which
higher plasma concentrations of LDL results in a greater
proportion of LDL-bound PCSK9, thereby inhibiting
PCSK9-mediated degradation of the LDL receptor [16].
In vitro evidence suggests that self-associated di-/trimers
have enhanced LDL receptor-binding and degrading
activity, compared with the monomer form [38]. PCSK9
also circulates as a 55 kDa furin-cleaved inactive fragment,
resulting from the cleavage of the 62 kDa protein: muta-
tions in the mature PCSK9 protein have been associated
with increased or decreased susceptibility to furin cleavage,
leading PCSK9 loss-of-function and gain-of-function phe-
notypes [22].
Mechanism of action
PCSK9 acts primarily as a soluble protein, targeting
degradation of the membrane-bound LDLR by extracellu-
lar binding via rerouting to the lysosomal pathway [39]. At
the molecular level, PCSK9 blocks the LDLR in an
extended (open) conformation. This is achieved when the
catalytic domain of PCSK9 (aa153–421) and the EGF-A
domain of LDLR (aa314–355) bind [40]. This failure of the
receptor to adopt a closed conformation results in a slowed
recycling to the plasma membrane and subsequent degra-
dation. LDL-receptors—like PCSK9—are particularly
abundant in the liver, the primary organ responsible for
clearance of plasma LDL. As the number of LDL-receptors
on the surface of liver cells determines the rate of LDL
removal from the bloodstream, PCSK9 presented an
appealing target to beneficially modulate lipid homeostasis.
Figure 2 illustrates the mechanism of action of PCSK9.
Impelled by promising pre-clinical evidence, the clinical
development of therapeutic inhibitors of PCSK9 has pro-
gressed rapidly, with promising results reported from phase
2 and 3 clinical studies, in statin-intolerant and familial




Several strategies have been proposed for targeting
PCSK9. Messenger RNA (mRNA) knockdown approaches,
which include the use of PCSK9 antisense oligonu-
cleotides, have been evaluated in animal models. Antisense
oligonucleotides administered to mice reduced PCSK9
expression by [90 % and lowered plasma cholesterol
levels by 53 % [41, 42]. A single intravenous injection of
PCSK9 RNA interference (RNAi) delivered in lipidoid
nanoparticles to cynomolgus monkeys reduced plasma
PCSK9 and LDL-C levels (by 70 and 56 %, respectively)
[43]. However, the use of monoclonal antibodies (mAb),
which interfere with the interaction of the PCSK9 catalytic
domain and LDLR, is particularly promising [44]. In
Fig. 1 Normal, physiological
LDLR recycling. LDL low
density lipoprotein, LDL-C low-
density lipoprotein cholesterol,
LDLR low density lipoprotein
receptor
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nonhuman primates, intravenous infusion of mAb1
(3 mg kg-1), which is specific for the catalytic domain of
PCSK9, resulted in marked (80 %) reduction in plasma
LDL-C [45].
PCSK inhibition may yield non-LDL-lowering, pleio-
tropic effects. High levels of lipoprotein(a) are an inde-
pendent predictor of cardiovascular mortality, even in
statin-treated patients with low LDL-C [46]. PCSK9
inhibitors reduce lipoprotein(a) by approximately 30 %.
Such an effect is not observed with statin- or ezetimibe-
mediated upregulation of LDL receptor activity (as
lipoprotein(a) is not cleared by LDLR-dependent mecha-
nisms, and is mainly regulated by hepatic secretion) [47].
Thus, PCSK9 inhibition as a therapeutic strategy has the-
oretical advantages beyond LDL-C lowering, raising the
possibility that cardiovascular outcomes may be addition-
ally favourable. Figure 3 displays the mechanism of action
of PCSK9 mAb, in the presence of a statin.
In clinical studies, three monoclonal antibodies have
demonstrated significant promise: evolocumab (AMG-
145), alirocumab (SAR236553/REGN727) and bococizumab;
the latter of which is in the early stages of development.
Table 1 lists PCSK9 inhibitors in development.
Evolocumab
Evolocumab in primary hypercholesterolemia
Evolocumab is a fully human monoclonal antibody inhi-
bitor of PCSK9. In the Monoclonal Antibody Against
PCSK9 to Reduce Elevated LDL-C in Patients Currently
Not Receiving Drug Therapy for Easing Lipid Levels
(MENDEL) trial, 406 patients with hypercholesterolaemia
and statin intolerance were randomly assigned to evolo-
cumab 70, 105 and 140 mg every 2 weeks; evolocumab
280, 350 and 420 mg every 4 weeks; placebo every
2 weeks or every 4 weeks, or ezetimibe once-daily. Evo-
locumab reduced LDL-C concentrations in all dose groups,
with the maximal effect for the regimen of 140 mg every
2 weeks (*51 %) and no reported treatment-related
adverse events [48].
MENDEL-2 evaluated the efficacy, safety and tolera-
bility of evolocumab compared with placebo and oral
ezetimibe in 614 patients with hypercholesterolemia
(LDL-C 100–190 mg dL-1 or 2.6–4.9 mmol L-1) [49].
Patients 18–80 years of age with Framingham risk scores
C10 % were randomised to one of six groups; (i) oral
placebo and sub-cutaneous (SC) placebo fortnightly; (ii)
oral placebo and SC placebo monthly; (iii) ezetimibe and
SC placebo fortnightly; (iv) ezetimibe and SC placebo
monthly; (v) oral placebo and evolocumab 140 mg fort-
nightly; or (vi) oral placebo and evolocumab 420 mg
monthly. Evolocumab treatment produced greatest
reductions in LDL-C from baseline, by 55–57 % more
than placebo and 38–40 % more than ezetimibe (both
p\ 0.001).
In the LDL-C Assessment With PCSK9 monoclonal
Antibody Inhibition Combined With Statin therapy
(LAPLACE TIMI-57), 631 patients with hypercholes-
terolemia on statins were randomised to different regimens
of evolocumab, with varying dosages and intervals of
administration: 70 mg, 105 mg, and 140 mg or matching
Fig. 2 Mechanism of action of
PCSK9. LDL low density
lipoprotein, LDL-C low-density
lipoprotein cholesterol, LDLR
low density lipoprotein receptor,
PCSK9 proprotein convertase
subtilisin/kexin type 9
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placebo every 2 weeks; or 280 mg, 350 mg, and 420 mg or
matching placebo every 4 weeks [50]. At week 12, the
mean LDL-C concentration reduction was dose-dependent,
ranging from 41.8 to 66.1 % every 2 weeks, and from 41.8
to 50.3 % every 4 weeks [51]. The LAPLACE-2 trial
assessed the response to addition of evolocumab (140 mg
every 2 weeks or 420 mg monthly) vs. placebo, to mod-
erate- or high-intensity statin therapy in 1896 patients with
hyperlipidaemia [52]. The trial observed that evolocumab
reduced plasma LDL-C concentrations by 66–75 %, vs.
placebo, at the mean of weeks 10 and 12. Evolocumab
added to statin therapy resulted in additional LDL-C
lowering.
More recently, the Durable Effect of PCSK9 Antibody
CompARed wiTh placEbo Study (DESCARTES) placed
patients into one of four background lipid-lowering
strategies (dietary changes alone, dietary changes plus
atorvastatin 10 mg, dietary changes plus atorvastatin
80 mg, and dietary changes plus atorvastatin 80 mg and
ezetimibe 10 mg) based on their LDL-C levels and car-
diovascular risk [53]. Individuals with LDL-C C75 mg/dl
were randomised to receive monthly SC evolocumab
420 mg or placebo. The mean reduction in LDL-C from
baseline in the evolocumab group was 57.0 ± 2.1 %
(p\ 0.001 vs. placebo). The mean reduction was
55.7 ± 4.2 % among patients who underwent dietary
Fig. 3 Mechanism of action of
PCSK9 mAb in presence of a
statin. LDL low density
lipoprotein, LDL-C low-density
lipoprotein cholesterol, LDLR
low density lipoprotein receptor,
PCSK9 proprotein convertase
subtilisin/kexin type 9
Table 1 | PCSK9 Inhibitors undergoing preclinical and clinical evaluation
Pharmaceutical company Drug class Agent Phase
Sanofi/Regeneron Human mAb Alicocumab (SAR236553/REGN727) 3
Amgen Human mAb Evolocumab (AMG 145) 3
Pfizer/Rinat mAb Bococizumab (RN316) 3
Novartis mAb LGT-209 2
Roche/Genetech mAb RG7652 2
Alnylam Pharmaceuticals/The Medicines Company siRNA oligonucleotide ALN-PCS02 1
Bristol-Myers Squibb/Adnexus Monobody BMS-962476 1
Idera Pharmaceuticals Antisense Oligonucleotide TBD PC
Merck mAb 1D05-IgG2 PC
Schering-Plough Mimetic peptides LDL EGF-AB peptide fragment PC
mAb monoclonal antibody, PC pre-clinical, siRNA small interfering ribonucleic acid
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changes alone, 61.6 ± 2.6 % among those who received
10 mg of atorvastatin, 56.8 ± 5.3 % among those who
received 80 mg of atorvastatin, and 48.5 ± 5.2 % among
those who received a combination of 80 mg of atorvastatin
and 10 mg of ezetimibe (p\ 0.001 for all comparisons).
Evolocumab treatment also significantly reduced levels of
apolipoprotein B, lipoprotein(a) and triglycerides.
Evolocumab in familial hypercholesterolemia
In the Reduction of LDL-C with PCSK9 Inhibition in
Heterozygous Familial Hypercholesterolemia Disorder
(RUTHERFORD) trial, 167 patients with heterozygous FH
(HeFH) and poorly-controlled LDL-C (C2.6 mmol L-1 or
100 mg dL-1) despite maximally-tolerated statin therapy,
were randomised 1:1:1 to receive evolocumab 350 mg,
420 mg or matched placebo, every four weeks. A sub-
stantial reduction in LDL-C was observed (43 % for
350 mg vs. 55 % for 420 mg) in addition to that due to
high-intensity statin therapy [54]. RUTHERFORD-2 sub-
sequently evaluated evolocumab in combination with other
lipid-lowering therapies in patients with HeFH [55]. In
total, 331 HeFH patients unable to achieve target LDL-C
(defined as per RUTHERFORD) despite maximally-toler-
ated statin alone, or in combination with ezetimibe, were
randomised 2:1 to receive evolocumab 140 mg every
2 weeks, evolocumab 420 mg monthly, or matched placebo,
for 12 weeks. Based on the Simon Broome criteria, 80 % of
participants had definite FH; 20 % had probable FH. All
patients received a statin; two-thirds received ezetimibe.
Both schedules demonstrated significant reduction in mean
LDL-C at week 12 (59.2 % for 140 mg every 2 weeks vs.
61.3 % for 420 mg monthly; both p\ 0.0001).
Classically, homozygous FH (HoFH) patients were
thought to have dual null mutations, conferring no LDL
receptor activity, and thus would not be expected to
respond to PCSK9 inhibition (which is LDL receptor-
dependent). Indeed, a small proportion of FH patients are
true genetic homozygotes, with identical null or loss-of-
function mutations in both alleles of the affected gene.
However, advanced genetic profiling has demonstrated that
most patients with homozygous loss-of-function mutations
are actually compound heterozygotes, with different
receptor mutations. As such, HoFH patients may be phe-
notypically stratified using fibroblast culture; those with
\2 % of LDL uptake are receptor negative; those with
2–25 % are receptor defective, compared to wild-type
controls [56]. Thus, patients with HoFH may still have a
degree of functional LDL receptor activity, which is
associated with severity of LDL cholesterol elevation, and
may be modulated via PCSK9 inhibition. Indeed, in the
recent Trial Evaluating PCSK9 Antibody in Subjects With
LDL Receptor Abnormalities (TESLA) Part B study, 50
patients with HoFH, on stable lipid-lowering therapy and
not on lipoprotein apheresis, received evolocumab 420 mg
monthly, in addition to statin therapy and other lipid-low-
ering medications [57]. Indeed, TESLA demonstrated that
in the Evolocumab-treated HoFH patients, LDL-C was
reduced by 31 % from baseline at week 12 compared with
placebo (p\ 0.0001); no serious adverse side effects were
noted.
Evolocumab in statin-intolerant patients
With infrequent reports of adverse effects, PCSK9 inhibi-
tors have been heralded as a potentially effective alterna-
tive treatment option for those who are statin-intolerant.
Muscle-related side effects (MRSE) are the commonest
reason given for discontinuation of statins. Worldwide, the
incidence of myopathy is 1.5–5 % of statin-treated
patients, although this is highly-dependent on the definition
used [58]. One study found that mild-to-moderate muscular
symptoms occurred more frequently in patients treated
with high-dose statins in clinical practice (in 10.5 %),
compared to randomised trials [59]. However, another
reported that most patients discontinuing statins due to
MRSE that are re-challenged demonstrate good tolerance
long-term [60]. Despite the uncertainties regarding the true
incidence of MRSE, there is a clear clinical need for
alternative therapies in patients at high cardiovascular risk,
with more severe degrees of myotoxicity [58].
The Goal Achievement After Utilizing an Anti-PCSK9
Antibody in Statin Intolerant Subjects (GAUSS) study
aimed to establish whether there was an advantage to
evolocumab over ezetimibe in this context [61]. In the
GAUSS trial, 160 patients with statin intolerance were
randomised to 5 groups: evolocumab alone at 280, 350,
420 mg, evolocumab at 420 mg with 10 mg ezetimibe
once-daily, or 10 mg ezetimibe plus placebo once-daily.
Statin intolerance was defined as the inability to tolerate at
least one statin at any dose, or an increase in dose, because
of intolerable myalgia (muscle pain, soreness, weakness, or
cramps) or myopathy (myalgia plus elevated creatine
kinase) and having symptom improvement or resolution
with statin discontinuation. The administration of evolo-
cumab was significantly associated with a reduction in
LDL-C levels, ranging from 40 to 65 %, with good toler-
ability; myalgia was reported in: 7.4 % receiving evolo-
cumab alone, 20 % receiving the evolocumab and
ezetimibe combination, and 3.1 % receiving ezetimibe and
placebo [61]. GAUSS-2 assessed statin-intolerant hyper-
lipidaemic patients [62, 63]. Intolerance was defined as
inability to tolerate any dose, or increase the dose above the
smallest tablet strength, because of intolerable muscle-
related side effects. Evolocumab (140 mg every 2 weeks or
420 mg monthly) reduced LDL-C from baseline by 53 and
410 J. Latimer et al.
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56 % respectively, when compared with ezetimibe
(37–39 % reduction from baseline; p\ 0.001). MRSE
occurred in 12 % of evolocumab-treated patients vs. 23 %
of ezetimibe-treated patients.
Evolocumab and cardiovascular outcomes
In the OSLER (Open Label Study of Long Term Evalua-
tion Against LDL-C) trial, 4465 patients were randomised
to receive either evolocumab 420 mg monthly, or 140 mg
every two weeks, and followed up for a median of
11.1 months. The results demonstrated that evolocumab
reduced the plasma concentration of LDL cholesterol by
61 %, from a median of 120 mg dL-1 (3.1 mmol L-1) to
48 mg dL-1 (1.2 mmol L-1; p\ 0.001). The rate of a
composite cardiovascular endpoint (defined as death, acute
coronary syndrome, heart failure, stroke or a transient
ischaemic attack) at 1 year was reduced from 2.18 % in the
standard-therapy group to 0.95 % in the evolocumab group
[Hazard Ratio (HR) 0.47; 95 % confidence interval (95 %
CI) 0.28–0.78; p = 0.003). A large proportion of these
patients were receiving statin therapy at baseline (69.7 %
of evolocumab-treated patients vs. 70.9 % of those
receiving placebo), though no conclusions are drawn
regarding the efficacy of evolocumab over and above statin
therapy. Table 2 displays phase 2 studies evaluating
evolocumab.
Alirocumab
Effect of alirocumab in primary hypercholesterolemia
Alirocumab is a fully human monoclonal antibody to
PCSK9. Phase II trials demonstrated that as monotherapy,
alirocumab can reduce LDL-C as much as intensive statin
treatment [64]. The phase III, double-blind, double-dummy
ODYSSEY-MONO trial evaluated the safety and efficacy
of alirocumab as monotherapy in comparison with eze-
timibe, over 24 weeks in patients with primary hyperc-
holesterolemia and moderate cardiovascular risk, not
otherwise receiving statins or other lipid-lowering therapy
[65]. A total of 103 patients with LDL-C 2.6–4.9 mmol
L-1 (100–190 mg dL-1), and 1–5 % 10-year risk of fatal
cardiovascular events (estimated via the Systematic COr-
onary Risk Evaluation [SCORE] tool) were randomised to
receive either ezetimibe 10 mg or alirocumab, with the aim
to achieve target HDL-C using the minimum effective dose
of anti-PCSK9 antibody. Alirocumab was initially self-
administered at a dose of 75 mg every 2 weeks, and up-
titrated to 150 mg if LDL-C at week 8 was[1.8 mmol L-1
(70 mg dL-1). Mean LDL-C reductions of 47 % with
alirocumab vs. 16 % with ezetimibe were observed (in-
tention-to-treat analysis; p\ 0.0001; 54 vs. 17 %, on-
treatment analysis; p\ 0.0001). Prior to up-titration, alir-
ocumab 75 mg every 2 weeks reduced LDL-C by 53 %,
indicating low-dose alirocumab is sufficient to provide
50 % LDL-C reduction in the majority of patients.
The ODYSSEY-COMBO trials evaluated the efficacy of
alirocumab in addition to maximally-tolerated daily statin
therapy vs. ezetimibe, in patients with hypercholes-
terolemia and additional CVD risk factors [66, 67]. In
ODYSSEY-COMBO II, alirocumab lowered LDL-C levels
significantly more than ezetimibe, at both week 24 (50.6
vs. 20.7 % respectively; p\ 0.0001) and 52 (49.5 vs.
18.3 % respectively; p\ 0.001). In addition, more alir-
ocumab-treated than ezetimibe-treated patients achieved
target LDL-C levels (B1.8 mmol L-1, B70 mg dL-1) by
week 24 (77 vs. 45.6 %; p\ 0.0001). The ODYSSEY-
OPTIONS studies demonstrated that the addition of alir-
ocumab to statin regimens produced significantly greater
LDL-C reductions than the addition of ezetimibe, doubling
of statin dose, or switch to high-potency agent such as
rosuvastatin [68, 69].
Alirocumab in familial hypercholesterolemia
The ODYSSEY programme (comprising ODYSSEY-FH I,
II, HIGH FH and LONG-TERM trials) assessed the effi-
cacy and safety of alirocumab in HeFH subjects with LDL-
C treatment targets dependent on cardiovascular risk status:
\2.6 mmol L-1 (\100 mg dL-1) in patients without
documented CVD and\1.8 mmol L-1 (\70 mg dL-1) in
patients with prior CVD [70–72]. Alirocumab administered
at 75 or 150 mg every 2 weeks reduced LDL-C by 48.8 %
in FH I and 48.7 % in FH II, respectively, from baseline to
week 24, compared with an increase in the placebo arms
(9.1 % in FH I; 2.8 % in FH II, respectively; p\ 0.0001
for all comparisons). By week 24, more alirocumab-treated
patients reached LDL-C treatment goals vs. placebo-treated
patients (72.2 vs. 2.4 % in FH I, and 81.4 vs. 11.3 % in FH
II; both p\ 0.0001). The mean achieved LDL-C levels in
alirocumab-treated patients were 1.92 mmol L-1 (74.3 mg
dL-1; FH I) and 1.70 mmol L-1 (65.9 mg dL-1; FH II) at
week 52. ODYSSEY LONG-TERM assessed the long-
term safety and tolerability of alirocumab in 2341 patients
with either: (i) HeFH, with or without manifestations of
CVD, or (ii) primary hypercholesterolemia and coronary
artery disease, with LDL-C inadequately controlled despite
maximally-tolerated lipid-modifying pharmacotherapy
(44 % received a high-intensity statin at recruitment)
[73]. At 24 weeks, mean LDL-C was reduced from
baseline by 61 % for alirocumab-treated patients, and
increased by 0.8 % for patients treated with placebo
(p\ 0.0001). LDL-C goals of C50 % reduction from
baseline were attained in alirocumab-treated patients vs.
placebo (76 % vs. 2 % p\ 0.0001 for LDL-C\2.6 mmol
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L-1 or \100 mg dL-1 and 81 vs. 9 %; p\ 0.0001 for
LDL-C\ 1.8 mmol L-1 or\ 70 mg dL-1). Most
recently, these results have been reported to be maintained
up to 78 weeks of treatment, with good tolerance [74].
Table 3 displays phase 2 studies evaluating alirocumab.
The safety of PCSK9 inhibition
So far, the clinical experience with monoclonal antibodies
directed toward PCSK9 suggests that they are safe and
well-tolerated, with no major safety issues and no evidence
of serious drug-related adverse events [75]. The most
common adverse events were nasopharyngitis, upper res-
piratory tract infections, influenza-like symptoms and back
pain; injection site reactions were infrequent (\2 and\4 %
of alirocumab and ezetimibe-treated patients, respectively)
[76]. Isolated reports of adverse effects include: gener-
alised pruritus after the first dose of alirocumab [64],
delayed hypersensitivity-type reaction with rash, 12 days
following the second injection of alirocumab [77], and a
case of cutaneous leucocytoclastic vasculitis reported
9 days after initiation of alirocumab [78]. All of these
patients responded well to withdrawal of the trial drug.
Regarding completed phase III trials, in GAUSS-2, MRSE
occurred in 12 % of evolocumab-treated, and 23 % of
ezetimibe-treated patients [62]; in LAPLACE-2, adverse
events were reported in 36, 40, and 39 % of evolocumab-,
ezetimibe- and placebo-treated patients, respectively [52].
None of the evolocumab-treated patients developed serious
adverse reactions. However, elevations in creatine kinase
(CK) of 3–10 times the upper limit of normal have been
reported in a total of 12 study drug-treated, and 4 placebo-
treated patients. No deaths due to serious adverse events
have been reported in PCSK9 clinical trials to date. Table 4
displays selected phase 3 studies of anti-PCSK9 mAbs.
One putative concern regarding this new class of
cholesterol-lowering drugs is the potential for hypoc-
holesterolaemia-associated adverse effects, such as cogni-
tive impairment. Indeed, even allowing for the technical
difficulties of accurate LDL-C measurement at severely
low levels, many subjects in phase 2 trials reached very
low concentrations of LDL-C. Among those treated with
alirocumab (150 mg every 2 weeks, for 12 weeks) in
addition to atorvastatin, mean LDL-C was only
0.88 ± 0.41 mmol L-1 (34 ± 16 mg dL-1) [78]. Prelimi-
nary analyses have not shown any evidence of a treatment-
related increase in cognitive impairment [79]. Some studies
have suggested an increased risk of haemorrhagic stroke at
lower cholesterol concentrations [80]. The identification of
rare patients with double loss of function (LOF) mutations
in the PCSK9 gene provides some reassurance, however.
Such individuals, who have very low plasma PCSK9 and
LDL-cholesterol concentrations, appear healthy and with-
out cardiovascular or neurocognitive impairment [81]. In
addition, plasma LDL-C does not relate directly to the
intracellular cholesterol concentrations involved in
Table 3 Completed phase II trials of alirocumab
Author
(reference)
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physiological functions (e.g. synthesis of hormones and
vitamins) and thus, such concerns may be misplaced.
Future directions
Impelled by the growing evidence-base regarding the
safety and efficacy of monoclonal PCSK9 inhibitors, con-
siderable momentum has accumulated in the translation of
this novel pharmacotherapeutic paradigm to clinical prac-
tice. However, there is still a need to evaluate whether
PCSK9 inhibition yields benefits on cardiovascular end-
points, for patients with primary hypercholesterolemia.
Indeed, three large phase III programmes with anti-PCSK9
monoclonal antibodies are currently ongoing to offer
definitive insights into their utilisation in preventing car-
diovascular events and improving clinical outcome: the
PROFICIO and FOURIER programmes evaluating evolo-
cumab, and the ODYSSEY programme evaluating alir-
ocumab. A list of currently ongoing clinical studies is
presented in Table 5. These trials are due to report in
2017–2018, and will surely offer greater insights into the
safety and efficacy of PCSK9 inhibition, particularly with
regard to effects over and above statin therapy.
In July 2015, the United States Food and Drug
Administration (FDA) approved alirocumab as a second-
line treatment, for adults with HeFH, and those with proven
CVD with hypercholesterolemia refractory to diet modifi-
cation and maximally-tolerated statin therapy. One month
later, the FDA similarly approved evolocumab for clinical
usage. These approvals were conditional on the subsequent
completion of planned phase III trials to determine efficacy
in primary hypercholesterolemia. Both agents have also
recently received marketing authorisation by the European
Medicines Agency.
Pharmacogenetic considerations
Although the PCSK9 locus is polymorphic, evidence has
not yet emerged to suggest that routine genetic testing
would predict responsiveness to PCSK9 inhibition, in
patients with primary hypercholesterolaemia. In patients
with HoFH, there exists evidence of differential response to
PCSK9 inhibition, dependent on the specific underlying
causative gene mutation(s). Evolocumab was demonstrably
effective in lowering LDL-C, only in patients with residual
LDL receptor function (the receptor-defective phenotype;
2–25 % function), but not receptor negative patients [54,
55, 57]. Stratification of FH patients, via fibroblast culture
or pharmacogenetic testing (which many candidates may
have underwent as part of FH diagnosis), may allow
Table 5 Major ongoing clinical studies of PCSK9 inhibitors
Title Description Study
identifier
Trial assessing efficacy, safety and tolerability of PCSK9
inhibition in paediatric subjects with genetic LDL disorders
10–17 year olds with outcomes focused on cardiovascular
risk
NCT02392559
Effects of selective inhibition of cholesterol absorption with
ezetimibe on intestinal cholesterol homeostasis in dyslipidemic
men with insulin-resistance—a pilot study
Aged 18–60 and has metabolic syndrome NCT01849068
Evaluating PCSK9 binding antibody influence on cognitive health
in high cardiovascular risk subjects
Testing spatial working memory in those aged 40 to 85
taking evolocumab
NCT02207634
Further cardiovascular outcomes research with PCSK9 inhibition
in subjects with elevated risk
5 year cardiovascular death, myocardial infarction,
hospitalization for unstable angina, stroke, or coronary
revascularization
NCT01764633
The evaluation of bococizumab (PF-04950615; RN316) in
reducing the occurrence of major cardiovascular events in high
risk subjects
Effect of bococizumab on number of Cardiovascular
Events
NCT01975389
A phase 1 study of an investigational drug, ALN-PCSSC, in
subjects with elevated low density lipoprotein cholesterol (LDL-
C)
Safety NCT02314442
A 2-part, phase 1, single and multiple ascending dose study to
assess the safety, pharmacokinetics, and pharmacodynamics of
CAT-2054 in healthy subjects
Frequency and severity of adverse events NCT02374047
Open label study of long term evaluation against LDL-C trial-2 Incidence of adverse events NCT01854918
ODYSSEY outcomes: evaluation of cardiovascular outcomes after
an acute coronary syndrome during treatment with alirocumab
SAR236553 (REGN727)
To evaluate the effect of alirocumab on any adverse
cardiovascular event
NCT01663402
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personalised prediction of responsiveness to PCSK9
inhibition.
Pharmacoeconomic considerations
Since the approval of these agents by regulatory bodies, the
uptake of PCSK9 inhibitors in US clinical practice has in
large, been slow. This may be explained by several key
factors. Priced over $14,000 per year before discounts
($14,100 for evolocumab, $14,600 for alirocumab), and
with a paucity of definitive data regarding improvements in
cardiovascular outcomes, insurers have been reluctant to
fund the available PCSK9 inhibitors. Recent pharma-
coeconomic analysis by the US Institute for Clinical and
Economic Review, calculated the overall price, best rep-
resenting the potential benefits to patients, would be
between $3615 and 4811—a 67 % discount on the current
list price [82]. However, when compared to apheresis (the
current best-available, alternative treatment, following
statin and second-line medical therapy for uncontrolled
hypercholesterolaemia), which costs approximately $8000
per month ($96,000 per year), the price of evolocumab and
alirocumab appear more attractive. Schulman et al. esti-
mate that in a typical insurance pool, if 5 % of the esti-
mated 27 % of US adults 40–64 years of age who have
hypercholesterolaemia were eligible for a PCSK9 inhibitor,
annual premiums would increase by approximately $124
per person; taxpayers would face the burden of similar
increases in the cost of the Medicare Part D program [83].
Conclusions
A quarter century after approval of the first statin in 1987,
reduction of LDL-C remains the best-validated treatment
strategy in preventing cardiovascular disease. PCSK9 is a
promising molecular target to reduce levels of LDL-C and
other atherogenic lipoproteins, below levels achievable
with statins. However, uncertainties remain regarding the
long-term impact of therapeutic reduction of plasma LDL-
C to very low concentrations (\1 mmol L-1). Addition-
ally, the increased risk of progression to diabetes seen with
high-intensity statin treatment might also occur with
PCSK9 inhibition, possibly resulting from the intracellular
accumulation of lipids in insulin-secreting pancreatic beta
cells [84]. However, more data are needed from large trials
to exclude important emergent adverse effects of PCSK9
inhibitors. Although self-administered injections might not
appear attractive for lifelong treatment, this route of
administration may be acceptable to high-risk patients,
unable to tolerate statins, or who need to achieve more
stringent LDL-C targets. There seems little doubt that the
advent of therapeutic PCSK9 inhibition heralds a change to
the future of lipid management.
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